U.S. Food and Drug Administration Approves Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients

KING OF PRUSSIA, PA – September 28, 2020– CSL Behring, a global biotherapeutics leader, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Haegarda® (C1 Esterase Inhibitor...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news